Secondary dyslipidemias

Czech version

Authors: V. Vargová ¹; M. Pytliak ²; V. Mechírová2 ^,3
Authors‘ workplace: III. interná klinika Lekárskej fakulty UPJŠ a UN L. Pasteura Košice, Slovenská republika, prednosta prof. MUDr. Daniel Pella, PhD. ¹; Ústav ošetrovateľstva Lekárskej fakulty UPJŠ Košice, Slovenská republika, prednostka prof. MUDr. Viola Mechírová, CSc. ²; I. interná klinika Lekárskej fakulty UPJŠ a UN L. Pasteura Košice, Slovenská republika, prednostka prof. MUDr. Ivica Lazúrová, CSc ³
Published in: Vnitř Lék 2012; 58(3): 221-227
Category: Reviews

Overview

Dyslipidemias rank among the most important preventabile factors of atherogenesis and its progression. This topic is increasingly being discussed as e.g. more than 50% of Slovak population die on atherosclerotic complications. According to etiology we distinguish primary dyslipidemias with strictly genetic background and secondary ones with origin in other disease or pathological state. Secondary dyslipidemias accompany various diseases, from common (endocrinopathies, renal diseases etc) to rare ones (thesaurismosis etc.) and represents one of symptoms of these diseases. Apart from particular clinical follow up of diagnosed dysipidemias, basic screening and secondary causes as well as treatment due to updated guidelines is recuired. In this review we present the most frequent dyslipidemias of clinical practice.

Key words:
secondary dyslipidemia – diabetes mellitus – nefrotic syndrome – cholestasis – alcohol

Sources

1. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115–126.

2. Anitschkow N, Chalatow S. Über experimentelle cholesterinäse und ihre Bedeutung für die Entstehung einiger pathologischer Prozesse. Zbl Allg Pathol Anat 1913; 24: 1.

3. The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes 1986; 35: 530–545.

4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

5. Vráblik M, Češka R. Sekundární dyslipoproteinémie. Via pract 2004; 1: 14–17.

6. Wilson PW, Kannel WB, Anderson KM. Lipids, glucose tolerance and vascular disease: the Framingham Study. Monogr Atheroscler 1985; 13: 1–11.

7. Fábryová Ľ. Diabetická dyslipidémia – dôležitá súčasť komplexnej starostlivosti o diabetikov 2. typu. Via pract 2005; 2: 6–10.

8. Štulc T, Češka R. Léčba dyslipidemie u metabolického syndromu. Vnitř Lék 2009; 55: 626–630.

9. Tkáč I, Fábryová Ľ, Klimeš I et al. Manažment dyslipidémií u pacientov s diabetes mellitus. Vyjadrenie stanoviska Slovenskej diabetologickej spoločnosti. Interná Med 2004; 4: 311–317.

10. Vaverková H, Soška V, Rosolová H et al. Czech Atherosclerosis Society. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53: 181–197.

11. Bláha V, Mistrík E. Hypolipidemika a diabetes mellitus. Vnitř Lék 2009; 55: 357–362.

12. Češka R, Tesař V. Diabetes, dyslipidemie a onemocnění ledvin. Vnitř Lék 2008; 54: 511–517.

13. Tkáč I. Stratégia prevencie rozvoja aterosklerózy pri diabete 2. typu. Kardiológia pre prax 2004; 3: 160–165.

14. Palmajová R. Význam kombinovanej hypolipidemickej liečby pre pacientov s metabolickým syndrómom. Interní medicína pro praxi 2009; 11: 298–300.

15. Babčák M, Merčiaková M, Kmec J et al. Diabetes mellitus 2. typ a artériová hypertenzia – najnovšie poznatky. Diabetes a obezita 2004; 4: 15–41.

16. Chawla V, Greene T, Beck GJ et al. Hyperlipidemia and Long-Term Outcomes in Nondiabetic Chronic Kidney Disease. Clin J Am Soc Nephrol 2010; 5: 1582–1587.

17. Chan CM. Hyperlipidaemia in chronic kidney disease. Ann Acad Med Singapore 2005; 34: 31–35.

18. Chamney M, Pugh-Clarke K, Kafkia T. Management of co-morbid diseases in a patient with established renal failure. J Ren Care 2009; 35: 151–158.

19. Wanner C, Krane V, Metzger T et al. Lipid changes and statins in chronic renal insufficiency and dialysis. J Nephrol 2001; 14 Suppl 4: S76–S80.

20. Sorokin A, Brown JL, Thompsona PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. Atherosclerosis 2007; 194: 293–299.

21. Studeník P. Poruchy metabolismu lipidů u jaterních onemocnění. Vnitř Lek 2000; 46: 547–548.

22. Duntas LH. Thyroid disease and lipids. Thyroid 2002; 12: 287–293.

23. Jiskra J. Změny svalové tkáně u hypothyreózy. Vnitř Lék 2001; 47: 609–612.

24. Graham I, Atar D, Borch-Johnsen K et al. European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375–2414.

25. Weinbrenner T, Züger M, Jakoby GE et al. Lipoprotein metabolism in patients with anorexia nervosa: a case – control study investigating the mechanisms leading to hypercholesterolaemia. Br J Nutr 2004; 91: 959–969.

26. Žák A, Vecka M, Tvrziská E et al. Composition of Plasma Fatty Acids and Non- Cholesterol Sterols in Anorexia Nervosa. Physiol Res 2005; 54: 443–451.

27. Hannuksela ML, Liisanantt MK, Savolainen MJ. Effect of alcohol on lipids and lipoproteins in relation to atherosclerosis. Crit Rev Clin Lab Sci 2002; 39: 225–283.

28. Pravdová E, Fisková M. Alcohol intake modulates hormonal activity of adipose tissue. Endocr Regul 2006; 40: 91–104.

29. Oneta CM. Pathogenese und Management der alkoholischen Lebererkrankung: Teil 2: Diagnostik und Behandlung. Schweiz Med Forum 2004; 4: 131–137.

30. Feinman L, Lieber CS. Ethanol and lipid metabolism. Editorial. Am J Clin Nutr 1999; 70: 791–792.

31. Soška V. Sekundární dyslipidémie a jejich léčba. Vnitř Lék 2007; 53: 396–401.

32. Imataka K. Alcohol or drug induced hyperlipidemia. Nippon Rinsho 1990; 48: 2599–2604.

33. Soška V, Fiala J, Nebeská K et al. Sekundární dyslipidemie navozená současnými perorálními kontraceptivy. Vnitř Lék 2009; 55: 929–933.

34. Saarelainen H, Laitinen T, Raitakari OT et al. Pregnancy-related hyperlipidemia and endothelial function in healthy women. Circ J 2006; 70: 768–772.

35. Fábryová Ľ. Algoritmus diagnostiky a liečby dyslipoproteinémií. Interná medicína 2010; 10: 3–14.